Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2016" report to their offering.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

This report provides comprehensive information on the therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned

  • Clementia Pharmaceuticals Inc
  • Daiichi Sankyo Company Ltd
  • Heart Metabolics Ltd
  • La Jolla Pharmaceutical Company
  • Oncodesign SA
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc

Key Topics Covered:

  1. Introduction
  2. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Overview
  3. Therapeutics Development
  4. Pipeline Products for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
  5. Pipeline Products for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Comparative Analysis
  6. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics under Development by Companies
  7. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics under Investigation by Universities/Institutes
  8. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Products under Development by Companies
  13. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Products under Investigation by Universities/Institutes
  14. Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/mkrps3/fibrodysplasia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Musculoskeletal Disorders Drugs